This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
Clinical and Immunogenicity Data of Pneumococcal Vaccines in Renal Diseases
As compared with the general population, increased mortality and morbidity from pneumococcal disease is observed in patients with CKD; the mortality rates being up to 10 to 16 times higher in patients undergoing dialysis. These patients are at a high risk of developing pneumococcal disease, and are also at a risk of vaccine hyporesponsiveness.1 There is scarcity of data on the efficacy of pneumococcal vaccines in patients with ESRD.2 Evidence indicates lowered immunologic response of patients with dialysis towards PPSV23, as compared with the general population. The anti-pneumococcal IgG levels decline rapidly in patients with ESRD 1 year after receiving PPSV23. A study evaluated the immunogenicity of PCV13 in 17 patients with ESRD who were on dialysis.2 The overall response to the individual vaccine serotypes ranged between 23.5% and 94.1% at 2 months, and 23.5% and 65% at 12 months post PCV13 administration. The study demonstrated that at 2 months post vaccination, PCV13 elicited good antibody response in dialysis patients. However, the response decreased 12 months post vaccination.1
A longitudinal quasi-experimental Phase IV study assessed the immunogenicity of PCV13 versus PPSV23 in 155 haemodialysis patients aged ≥50 years, with or without prior PPSV23 vaccination. Significant immune response was observed for at least 1 year after PCV13 and PPSV23 vaccination in patients who were not previously vaccinated with PPSV23. PCV13 was more immunogenic than PPSV23 in vaccine-naïve haemodialysis patients. Moreover, as compared with vaccine-naïve haemodialysis patients, PCV13 elicits weaker immune response in PPSV23 pre-vaccinated patients. Although the trial was not designed to draw conclusion on mortality, vaccine-naïve patients administered with PCV13 tended to have lower mortality than the other groups studied.2
CKD, chronic kidney disease; ESRD, end-stage renal disease; IgG, immunoglobulin G; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal plain polysaccharide vaccine.
References:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0268 July 2022
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Efficacy proven by the CAPiTA study
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.